RenovoCath

RenovoRx (formerly RenovoCath) is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. The company's proprietary RenovoTAMP (Therapeutic Angiographic Multi-Phase) platform utilizes the RenovoCath dual-balloon infusion catheter to deliver chemotherapy directly to the tumor site via the arterial system. This targeted approach aims to increase local drug concentration while minimizing systemic toxicity compared to standard intravenous administration. Their lead candidate, RenovoGem, consists of gemcitabine delivered via the RenovoTAMP platform and is currently in a Phase 3 clinical trial for locally advanced pancreatic cancer. RenovoRx is also exploring the platform's utility in other difficult-to-treat cancers, such as bile duct cancer. The company is headquartered in Los Altos, California, and is publicly traded on the Nasdaq.